Poor
Not Aligned
Patient Risk:
High
Summary
The AI claims largely reflect general/other aspirin labeling and do not match the provided FDA-approved prescribing information for the specific product (Aspirin and Extended-Release Dipyridamole Capsules). Major mismatches include indication (stroke risk vs cardiovascular prevention), dosing (twice daily capsule regimen), and multiple warnings/interaction details not supported by the provided label excerpts. Several safety assertions are unsupported or not evidenced in the supplied sections.
Category Scores
Accurate Statements
Daily aspirin increases the risk of stomach ulcers and bleeding.
SECTION 5.1 (warnings include GI side effects and that physicians should remain alert for signs of ulceration and bleeding; product increases risk of bleeding).
Unsupported Statements
Low-dose aspirin typically 75–100 mg daily is a common regimen for long-term cardiovascular prevention in adults at risk of heart attack or stroke.
Not supported by the provided label excerpts; the provided indication is specific to reducing stroke risk in TIA/completed ischemic stroke due to thrombosis (SECTION 1), and no cardiovascular prevention dose range is provided.
Long-term low-dose aspirin is usually taken once a day.
The provided label dose is one capsule orally twice daily (morning and evening) (SECTION 2).
Low-dose aspirin is often taken with food to reduce stomach irritation.
Label states can be administered with or without food (SECTION 2) but does not state a purpose to reduce stomach irritation.
Aspirin is prescribed for secondary prevention after a heart event and for primary prevention in high-risk patients without prior events.
Not supported; provided indication for this product is to reduce risk of stroke in patients with TIA or completed ischemic stroke due to thrombosis (SECTION 1).
Aspirin daily use inhibits platelet aggregation to prevent clot formation.
The label’s mechanism for the combination is additive antiplatelet effects of dipyridamole and aspirin (SECTION 12.1), but the statement attributes the effect to aspirin alone and to 'daily use' broadly; not supported as stated.
Higher or more frequent aspirin doses increase bleeding risk without added benefit for chronic therapy.
Not supported by the provided label excerpts.
The frequency of aspirin never exceeds once daily for chronic therapy.
Not supported and conflicts with the provided product dosing (SECTION 2: twice daily capsule).
An 81 mg dose (common U.S. dose) is taken once daily for most long-term users.
No 81 mg dose or once-daily regimen is provided in the supplied label excerpts (SECTION 2 and 3 provided do not describe an 81 mg aspirin-alone dosing regimen).
325 mg aspirin is sometimes used short-term post-event, but is not routine for ongoing use due to higher gastrointestinal bleeding risk.
Not supported by provided label excerpts.
Enteric-coated aspirin does not change the dosing schedule.
Not addressed in provided label excerpts.
Daily aspirin increases the risk of bleeding including gastrointestinal or brain bleeding.
The label states increased risk of bleeding and provides intracranial hemorrhage and GI bleeding rates (SECTION 5.1), but the statement is overly general to 'daily aspirin' (aspirin alone) and not tied to the specific product; not supported as stated.
Daily aspirin can increase the risk of kidney issues.
The label specifically advises to avoid aspirin-containing products in severe renal failure (GFR <10 mL/min) (SECTION 5.2) and does not state that 'daily aspirin' increases risk of kidney issues generally.
Risks of daily aspirin increase with age over 70.
Not supported by provided label excerpts.
Concurrent NSAID use increases the risks of daily aspirin.
The label mentions chronic use of NSAIDs as a risk factor for bleeding (SECTION 5.1), but the statement is not supported as a general interaction 'increases the risks of daily aspirin' and is not specific to concomitant use as described.
Alcohol use increases the risks of daily aspirin.
The label only counsels patients who consume three or more alcoholic drinks every day about bleeding risks with chronic, heavy alcohol use (SECTION 5.1). The broader claim is not supported as stated.
Doctors may stop aspirin if bleeding occurs or switch to alternatives such as clopidogrel.
Not supported by provided label excerpts.
Clopidogrel is an alternative antiplatelet option for those intolerant to aspirin, at 75 mg daily.
Not supported by provided label excerpts.
Ticagrelor is an alternative antiplatelet option for those intolerant to aspirin, at twice daily dosing.
Not supported by provided label excerpts.
Skip missed aspirin doses and do not double up.
Not supported by provided label excerpts.
Aspirin overuse (for example, taking multiple times daily) increases bleeding risk.
Not supported by provided label excerpts.
Symptoms such as black stools or severe headache after taking aspirin require immediate medical attention.
The label advises patients to inform about signs/symptoms of GI side effects and what steps to take if they occur (SECTION 5.1), but specific examples and 'immediate medical attention' wording are not provided.
Low-dose aspirin is available over the counter.
Not addressed in provided label excerpts.
Contradictions
Low
AI Statement
Long-term low-dose aspirin is usually taken once a day.
Label Reference
SECTION 2 Dosage and Administration (recommended dose: one capsule orally twice daily, morning and evening).
Low
AI Statement
The frequency of aspirin never exceeds once daily for chronic therapy.
Label Reference
SECTION 2 Dosage and Administration (twice daily capsule regimen).
Important Omissions
Specific labeled indication for this product: reduce risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis (not general heart attack/stroke prevention).
Importance:
High
Labeled dosing/administration for this product: one capsule orally twice daily (morning and evening), swallow capsules whole without chewing; can be administered with or without food; not interchangeable with individual components.
Importance:
High
Labeled contraindications: hypersensitivity to components; aspirin contraindicated in NSAID allergy/aspirin allergy and in asthma/rhinitis/nasal polyps; do not use in children/teenagers with viral infections (Reye syndrome).
Importance:
High
Labeled warnings related to renal failure (avoid in severe renal failure GFR <10 mL/min), and detailed bleeding risk counseling; plus that dipyridamole-related stress testing requires interrupting for 48 hours (for certain agents).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple high-importance mismatches versus the provided label excerpts (indication and dosing frequency) plus several unsupported safety/management claims could lead to inaccurate use relative to labeled guidance for this specific product.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims describe general low-dose aspirin regimens for cardiovascular prevention and once-daily dosing, which are not supported by the provided FDA-approved prescribing information for Aspirin and Extended-Release Dipyridamole Capsules (labeled indication is stroke risk reduction in TIA/completed ischemic stroke due to thrombosis; labeled dosing is twice daily capsules).
Suggested Improvement
Restrict claims to the supplied label: state the product’s stroke-risk indication (SECTION 1), the labeled twice-daily capsule regimen and non-interchangeability (SECTION 2), and align bleeding/GI/alcohol/renal-failure precautions and interactions exactly with the provided excerpts (SECTION 5.1, 5.2, 7.1) rather than general aspirin guidance.